Colorectal Medullary Carcinoma Clinical Trial
Official title:
Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort Study
| NCT number | NCT03774862 |
| Other study ID # | VKVAmericanH |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | January 1, 2011 |
| Est. completion date | August 1, 2018 |
| Verified date | December 2018 |
| Source | V.K.V. American Hospital, Istanbul |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Medullary carcinoma (MC) is a rare tumor with solid growth pattern without glandular differentiation and constitute less than 1% of colorectal cancer. Lymph node positivity and distant organ metastasis were reported to be lower than other poorly differentiated adenocarcinomas. Therefore, the diagnosis of MC is pathologically important in terms of follow-up and treatment. MC is commonly localized in the right colon, has a large tumor size, and is mostly diagnosed in the T4 stage. As MC most likely have defects in DNA MMR, the correct pathological diagnosis is important for the postoperative treatment and the prognosis of the patients.
| Status | Completed |
| Enrollment | 13 |
| Est. completion date | August 1, 2018 |
| Est. primary completion date | December 31, 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - colorectal cancer diagnosis, medullary carcinoma Exclusion Criteria: |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| V.K.V. American Hospital, Istanbul |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Overall survival of medullar colorectal carcinomas | 7 years |